A 76-year-old white female presented for her periodic diabetic eye examination at UAB Eye Care in July 2014. She admitted to blurry vision in her left eye for approximately one week.
A study recently published in Ophthalmology found that nutritional supplements marketed to help treat age-related macular degeneration (AMD) may not be backed by scientific evidence.
According to a report from GlobalData, the age-related macular degeneration treatment market in the U.S., UK, Germany, France, Spain, Italy, and Japan will double in value from $5.1 billion in 2013 to $10.1 billion in 2023.
Check out the biggest retina stories of the year.
Konan Medical recently launched EvokeDx, the next-generation visual pathway diagnostics platform to assess visual evoked potentials (VEP) and electroretinograms (ERG).
Health Canada recently approved Eylea (aflibercept, Regeneron) for the treatment of diabetic macular edema (DME).
The U.S. Food and Drug Administration recently approved VisionCare Ophthalmic Technologies’ Implantable Miniature Telescope for use in patients living with bilateral end-stage age-related macular degeneration (AMD) who are age 65 or older.
An article recently published in Current Opinion in Ophthalmology looked to help eyecare practitioners understand the costs of genetic testing in ocular disease, the complexities of insurance coverage, and its impact on the availability of genetic testing.
The American Academy of Ophthalmology says that close to one-third of the nation's eye physicians and surgeons are participating in the Intelligent Research In Sight (IRIS) Registry, which is the first comprehensive database of eye diseases and conditions in the United States.
According to the National Eye Institute (NEI), 7.7 million people age 40 and older have diabetic retinopathy, and this number is projected to increase to approximately 11 million people by 2030.